What we offer
We offer expertise across all major asset classes, with investment teams situated around the world
Equities
We offer a wide range of equity strategies encompassing different geographic focuses and investment styles. The teams include those with a global perspective, those with a regional focus – Europe, US, Asia Pacific and Emerging Markets – and those invested in specialist sectors. A range of growth, value and absolute return styles are employed. These teams generally apply processes based on fundamental research and bottom-up stock picking.
Equities
US$256.6bn in assets under management*
Fixed income
Our Fixed Income teams provide coverage across the asset class, applying a wide range of differentiated techniques. These teams include those adopting global unconstrained approaches through to those with more focused mandates. The capabilities of these teams can be accessed through individual strategies and are combined where appropriate to form multi-strategy offerings.
Fixed income
US$155.8bn in assets under management*
Alternatives
The Janus Henderson Alternatives grouping includes teams with different areas of focus and approach. The Diversified Alternatives Team brings together a cross-asset class combination of alpha generation, risk management, and efficient beta replication strategies. These include multi-strategy, liquid alternatives, agriculture, and global commodities/managed futures.
Alternatives
US$22.0bn in assets under management*
Multi-asset
Janus Henderson Multi-Asset includes teams in the US and UK. In the US, our teams manage US and global asset allocation strategies. In the UK, we have asset allocation specialists, traditional multi-manager investors, and those focused on alternative asset classes.
Multi-asset
US$58.8bn in assets under management*
*As at 31 December 2025
Latest insights
Data center power: Why the key risk is under delivery, not overbuild
Why the prevailing narrative of new energy-generation capacity exceeding AI data center demand could be off the mark.
Read moreAI state of play: Shifting gears to autonomous and physical applications
AI is entering a new phase defined by reasoning led models, agentic systems and accelerating infrastructure investment.
Read morePharma and biotech in 2026: A catalyst‑rich year ahead
With innovation back in focus, a dense slate of drug launches, data readouts, and regulatory decisions makes 2026 a consequential year for pharma and biotech.
Read more